دسترسی یکساله به بیش از ۵۰۰ ژورنال روز جهان موجود در سامانه
-
http://medilib.ir
- ﻣﺪﺕ ﺯﻣﺎﻥ : 365 ﺭﻭﺯ
قیمت : 3,800,000 تومان- قیمت ویژه : 1,900,000تومان
Defining the targets in SLE management: insights and unmet gaps
Margherita Zen, Mariele Gatto, Andrea Doria
doi : 10.1136/ard-2022-222991
November 2022 - Volume 81 - 11
Diagnostic evaluation of the sacroiliac joints for axial spondyloarthritis: should MRI replace radiography?
Denis Poddubnyy, Torsten Diekhoff, Xenofon Baraliakos, Kay Geert A Hermann, Joachim Sieper
doi : 10.1136/ard-2022-222986
Infections in patients with rheumatoid arthritis receiving tofacitinib versus tumour necrosis factor inhibitors: results from the open-label, randomised controlled ORAL Surveillance trial
Andra-Rodica Balanescu, Gustavo Citera, Virginia Pascual-Ramos, Deepak L Bhatt, Carol A Connell, David Gold, All-Shine Chen, Gosford Sawyerr, Andrea B Shapiro, Janet E Pope, Hendrik Schulze-Koops
doi : 10.1136/ard-2022-222405
Age-associated B cells contribute to the pathogenesis of rheumatoid arthritis by inducing activation of fibroblast-like synoviocytes via TNF-α-mediated ERK1/2 and JAK-STAT1 pathways
Yi Qin, Ming-Long Cai, Hui-Zhi Jin, Wei Huang, Chen Zhu, Aline Bozec, Jingang Huang, Zhu Chen
doi : 10.1136/ard-2022-222605
Efficacy and safety of upadacitinib for active ankylosing spondylitis refractory to biological therapy: a double-blind, randomised, placebo-controlled phase 3 trial
Désirée van der Heijde, Xenofon Baraliakos, Joachim Sieper, Atul Deodhar, Robert D Inman, Hideto Kameda, Xiaofeng Zeng, Yunxia Sui, Xianwei Bu, Aileen L Pangan, Peter Wung, In-Ho Song
doi : 10.1136/ard-2022-222608
Pregnancy and neonatal outcomes in women with axial spondyloarthritis: pooled data analysis from the European Network of Pregnancy Registries in Rheumatology (EuNeP)
Yvette Meissner, Anja Strangfeld, Anna Molto, Frauke Forger, Marianne Wallenius, Nathalie Costedoat-Chalumeau, Hilde Bjørngaard, Marion Couderc, René-Marc Flipo, Gaëlle Guettrot-Imbert, Isabell Haase, Bente Jakobsen, Hege Suorza Svean Koksvik, Christophe Richez, Jérémie Sellam, Anja Weiß, Astrid Zbinden, Rebecca Fischer-Betz
doi : 10.1136/ard-2022-222641
Early identification of axial psoriatic arthritis among patients with psoriasis: a prospective multicentre study
Fabian Proft, Susanne Lüders, Theresa Hunter, Gustavo Luna, Valeria Rios Rodriguez, Mikhail Protopopov, Katharina Meier, Georgios Kokolakis, Kamran Ghoreschi, Denis Poddubnyy
doi : 10.1136/ard-2022-222562
Remission and low disease activity (LDA) prevent damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) inception cohort
Manuel Francisco Ugarte-Gil, John Hanly, Murray Urowitz, Caroline Gordon, Sang-Cheol Bae, Juanita Romero-Diaz, Jorge Sanchez-Guerrero, Sasha Bernatsky, Ann Elaine Clarke, Daniel J Wallace, David Alan Isenberg, Anisur Rahman, Joan T Merrill, Paul R Fortin, Dafna D Gladman, Ian N Bruce, Michelle Petri, Ellen M Ginzler, Mary Anne Dooley, Rosalind Ramsey-Goldman, Susan Manzi, Andreas Jönsen, Ronald F van Vollenhoven, Cynthia Aranow, Meggan Mackay, Guillermo Ruiz-Irastorza, Sam Lim, Murat Inanc, Ken Kalunian, Søren Jacobsen, Christine Peschken, Diane L Kamen, Anca Askanase, Bernardo A Pons-Estel, Graciela S Alarcón
doi : 10.1136/ard-2022-222487
Leflunomide versus azathioprine for maintenance therapy of lupus nephritis: a prospective, multicentre, randomised trial and long-term follow-up
Qiong Fu, Chunmei Wu, Min Dai, Suli Wang, Jianhua Xu, Lie Dai, Zhijun Li, Lan He, Xiaochun Zhu, Lingyun Sun, Liangjing Lu, Chunde Bao
doi : 10.1136/ard-2022-222486
Phase 3, multicentre, randomised, placebo-controlled study evaluating the efficacy and safety of ustekinumab in patients with systemic lupus erythematosus
Ronald F van Vollenhoven, Kenneth C Kalunian, Thomas Dörner, Bevra H Hahn, Yoshiya Tanaka, Robert M Gordon, Cathye Shu, Kaiyin Fei, Sheng Gao, Loqmane Seridi, Patrick Gallagher, Kim Hung Lo, Pamela Berry, Qing C Zuraw
doi : 10.1136/ard-2022-222858
Pathogenic neuropsychiatric effect of stress-induced microglial interleukin 12/23 axis in systemic lupus erythematosus
Nobuya Abe, Masato Tarumi, Yuichiro Fujieda, Nobuhiko Takahashi, Kohei Karino, Mona Uchida, Michihito Kono, Yuki Tanaka, Rie Hasebe, Masaru Kato, Olga Amengual, Yoshiyuki Arinuma, Kenji Oku, Wakiro Sato, Khin Khin Tha, Miwako Yamasaki, Masahiko Watanabe, Tatsuya Atsumi, Masaaki Murakami
doi : 10.1136/ard-2022-222566
Peroxisome proliferator activated receptor-γ agonist pioglitazone improves vascular and metabolic dysfunction in systemic lupus erythematosus
Sarfaraz Hasni, Yenealem Temesgen-Oyelakin, Michael Davis, Jun Chu, Elaine Poncio, Mohammad Naqi, Sarthak Gupta, Xinghao Wang, Christopher Oliveira, Dillon Claybaugh, Amit Dey, Shajia Lu, Philip Carlucci, Monica Purmalek, Zerai G Manna, Yinghui Shi, Isabel Ochoa-Navas, Jinguo Chen, Amrita Mukherjee, Kyu Lee Han, Foo Cheung, Galina Koroleva, Yasmine Belkaid, John S Tsang, Richard Apps, Donald E Thomas, Theo Heller, Massimo Gadina, Martin P Playford, Xiaobai Li, Nehal N Mehta, Mariana J Kaplan
doi : 10.1136/ard-2022-222658
SARS-CoV-2 Omicron escapes mRNA vaccine booster-induced antibody neutralisation in patients with autoimmune rheumatic diseases: an observational cohort study
Woo-Joong Kim, Seong-Ho Choi, Ji Young Park, Jung Soo Song, Jin-Won Chung, Sang Tae Choi
doi : 10.1136/ard-2022-222689
Immunogenicity induced by two and three doses of the BNT162b2 mRNA vaccine in patients with autoimmune inflammatory rheumatic diseases and immunocompetent controls: a longitudinal multicentre study
Victoria Furer, Tali Eviatar, Tal Freund, Hagit Peleg, Daphna Paran, David Levartovsky, Ilana Kaufman, Adi Broyde, Ofir Elalouf, Ari Polachek, Joy Feld, Amir Haddad, Tal Gazitt, Muna Elias, Nizar Higazi, Fadi Kharouf, Smadar Gertel, Sara Pel, Sharon Nevo, David Hagin, Devy Zisman, Ori Elkayam
doi : 10.1136/ard-2022-222550
Behçet’s disease risk-variant HLA-B51/ERAP1-Hap10 alters human CD8 T cell immunity
Ann Cavers, Matthias Christian Kugler, Yesim Ozguler, Arshed Fahad Al-Obeidi, Gulen Hatemi, Beatrix M Ueberheide, Didar Ucar, Olivier Manches, Johannes Nowatzky
doi : 10.1136/ard-2022-222277
Management and outcome of native joint septic arthritis: a nationwide survey in French rheumatology departments, 2016–2017
Pauline Richebé, Guillaume Coiffier, Pascal Guggenbuhl, Denis Mulleman, Marion Couderc, Emanuelle Dernis, Valentine Deprez, Carine Salliot, Saik urien, Rachel Brault, Adeline Ruyssen-Witrand, Emmanuel Hoppe, Emmanuel Chatelus, Christian hubert roux, Sebastien Ottaviani, Marie Baufrere, Alexia Michaut, Loic Pauvele, Christelle Darrieutort-Laffite, Daniel Wendling, Pascal Coquerelle, Géraldine Bart, Elisabeth Gervais, Vincent Goeb, Marc Ardizzone, Edouard Pertuiset, Sophie Derolez, Jean Marc Ziza, René-Marc Flipo, Sophie Godot, Raphaele Seror
doi : 10.1136/ard-2022-222143
Fever, rhinosinusitis and glomerulonephritis with systemic inflammation and antimyeloperoxidase antibody
Motohiro Yokota, Nobuya Abe, Miyuki Bohgaki, Hideki Kasahara
doi : 10.1136/ard-2022-222937
Rational use of tocilizumab in COVID-19
Siddharth Jain, Shefali Khanna Sharma
Targeting IL-6 in COVID-19. Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Pier Leopoldo Capecchi, Pietro Enea Lazzerini
Response to: ‘Rational use of tocilizumab in COVID-19’ by Jain and Sharma
Nicola Potere, Marcello Di Nisio, Donatella Cibelli, Rosa Scurti, Antonella Frattari, Ettore Porreca, Antonio Abbate, Giustino Parruti
Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine’ by Mathian et al
Quirin Notz, Patrick Meybohm, Peter Kranke, Dirk Weismann, Christopher Lotz, Marc Schmalzing
Response to: ‘Antirheumatic drugs, B cell depletion and critical COVID-19: correspondence on ‘Clinical course of coronavirus disease 2019 (COVID-19) in a series of 17 patients with systemic lupus erythematosus under long-term treatment with hydroxychloroquine by Mathian et al’ by Notz et al
Alexis Mathian, Zahir Amoura
Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID-19): a multicentre cohort’
Maria Vincenza Mastrolia, Rino Agostiniani, Chiara Azzari, Roberto Bernardini, Ugo Bottone, Giovanni Battista Calabri, Flavio Civitelli, Rita Consolini, Roberto Danieli, Rosalia Di Silvio, Susanna Falorni, Luigi Gagliardi, Salvatore Grosso, Marco Martini, Graziano Memmini, Diego Peroni, Marco Pezzati, Giovanni Suriano, Luca Tafi, Angelina Vaccaro, Pier Luigi Vasarri, Gabriele Simonini
Response to: ‘Correspondence on ‘Paediatric multisystem inflammatory syndrome temporally associated with SARS-CoV-2 mimicking Kawasaki disease (Kawa-COVID19): a multicentre cohort’’ by Mastrolia et al
Charlotte Borocco, Marie Pouletty, Caroline Galeotti, Ulrich Meinzer, Albert Faye, Isabelle Koné-Paut, Naim Ouldali, Isabelle Melki
Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al
Acer I-Hung Chen, Sheng-Chieh Lin, James Cheng-Chung Wei
Response to: ‘Correspondence on ‘Lung involvement in macrophage activation syndrome and severe COVID-19: results from a cross-sectional study to assess clinical, laboratory and artificial intelligence–radiological differences’ by Ruscitti et al’ by Chen et al
Piero Ruscitti, Federico Bruno, Onorina Berardicurti, Chiara Acanfora, Viktoriya Pavlych, Pierpaolo Palumbo, Alessandro Conforti, Francesco Carubbi, Ilenia Di Cola, Paola Di Benedetto, Paola Cipriani, Davide Grassi, Carlo Masciocchi, Annamaria Iagnocco, Antonio Barile, Roberto Giacomelli
Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases
Alessandro Giollo, Eugenia Bertoldo, Giovanni Adami, Adam J Cybulski, Angelo Fassio, Giovanni Orsolini, Luca Idolazzi, Davide Gatti, Ombretta viapiana, Maurizio Rossini
Rheumatic disease activity, glucocorticoid use and COVID-19. Response to: ‘Correspondence on ‘Characteristics associated with hospitalisation for COVID-19 in people with rheumatic disease: data from the COVID-19 Global Rheumatology Alliance physician-reported registry’ by Gianfrancesco et al. Disease activity, rather than glucocorticoid therapy, may be associated with COVID-19 severity in patients with rheumatic musculoskeletal diseases’ by Giollo et al
Kimme L Hyrich, Milena Gianfrancesco, Pedro M Machado, Jinoos Yazdany, Philip C Robinson
Correspondence to ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’
Wenjie Zheng, Pui-Ying Leong, James Cheng-Chung Wei
Response to ‘Correspondence on ‘Comparative effectiveness of first-line tumour necrosis factor inhibitor versus non-tumour necrosis factor inhibitor biologics and targeted synthetic agents in patients with rheumatoid arthritis: results from a large US registry study’’ by Zheng et al
Dimitrios A Pappas, Gregory St John, Carol J Etzel, Stefano Fiore, Taylor Blachley, Toshio Kimura, Rajeshwari Punekar, Kelechi Emeanuru, Jeannie Choi, Susan Boklage, Joel M Kremer
Correspondence on ‘Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort’ by Micheroli et al
Jin-Xian Huang, Pui-Ying Leong, James Cheng-Chung Wei
Response to: ‘Correspondence on ‘Effectiveness of secukinumab versus an alternative TNF inhibitor in patients with axial spondyloarthritis previously exposed to TNF inhibitors in the Swiss Clinical Quality Management cohort’ by Micheroli et al’ by Huang et al
Adrian Ciurea, Raphael Micheroli
Correspondence on ‘Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study’
Young Ho Lee
Response to: ‘Correspondence on ‘Systemic evaluation of the relationship between psoriasis, psoriatic arthritis and osteoporosis: observational and Mendelian randomisation study’ by Lee
Jiangwei Xia, Lin Xu, Ke-Qi Liu, Zhi-Min Ying, Shu-Yang Xie, Hou-Feng Zheng
Short duration antibiotic therapy for native joint arthritis caused by Neisseria infection?
Maïlys Ducours, Samar El-Hout, Arnaud Desclaux, Hervé Dutronc, Thylbert Deltombe, Thomas Fauthoux, François Vercruysse, Marie Kostine, Charles Cazanave
Response to: ‘Short duration antibiotic therapy for native joint arthritis cause by Neisseria infection?’ by Durcours et al
Ilker Uçkay, Konstantinos Vakalopoulos, Ergys Gjika
Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’
Yuri Muraviov, Ludmila Muraviova
Response to: ‘Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’’ by Muraviov and Muraviova
Piero Ruscitti, Tanja A Stamm, Roberto Giacomelli
Response to: ‘Correspondence on ‘Changing the outcome measures, changing the results? The urgent need of a specific disease activity score to adult-onset Still’s disease’’ by Muraviov and Muraviova
Claudia Kedor, Jan Zernicke, Eugen Feist
Correspondence on ‘Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study’
Po-Cheng Hung, Da-Hung Lin, Amy Ker, Chieh-Chun Yang, Hung-Wan Chien, James Cheng-Chung Wei
Response to: ‘Correspondence on ‘Ultrasound shows rapid reduction of crystal depositions during a treat-to-target approach in gout patients: 12-month results from the NOR-Gout study’’ by Hung et al
Hilde Berner Hammer, Lars Fridtjof Karoliussen, Lene Terslev, Espen A Haavardsholm, Tore K Kvien, Till Uhlig
Severe polymyalgia-like symptoms secondary to anti-PD1 therapy successfully managed without discontinuing checkpoint inhibitor
Carlos Antonio Moura, Carlos Geraldo Moura
Gender gap in rheumatology: speaker representation at annual conferences
Kanika Monga, Jean Liew
